Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.
INSR, a protein essential for insulin activity, plays a critical role in stem cell longevity. Additionally, inactivating INSR in glioblastoma brain cancer stem cells inhibits the growth of primitive tumor forming cells.
Researchers are currently recruiting patients for a Phase 1 trial of a new immunotherapy treatment for glioblastoma brain cancer.
A class of drugs called BACE1 inhibitors, originally designed to treat Alzheimer's disease, shows potential for the treatment of glioblastoma brain cancer.
Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.
A new STING treatment induces immunological responses that allow the immune system to fight otherwise immunological resistant glioblastoma cancer cells, researchers report.
While incidence rates of malignant brain cancers have declined over recent years, the five-year survival rate for brain cancer patients remains low.
Researchers have successfully replicated an entire, viable glioblastoma brain tumor via 3D bioprinting. The bioprinted tumor includes a complex system of blood vessel-like tubes through which blood cells and drug molecules can flow, simulating a real tumor.
Two newly developed tests, one which analyzes urine samples and a simple blood test, can detect the presence of glioma brain cancer.
